Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541–1552

Article  PubMed  Google Scholar 

Roberts KG, Mullighan CG (2015) Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol 12(6):344–357

Article  PubMed  Google Scholar 

Teachey DT, Hunger SP (2018) Acute lymphoblastic leukaemia in 2017: immunotherapy for ALL takes the world by storm. Nat Rev Clin Oncol 15(2):69–70

Article  PubMed  Google Scholar 

Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358(6381):15–16

Article  PubMed  Google Scholar 

Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(1):a001008

Article  PubMed  PubMed Central  Google Scholar 

Mullighan CG (2012) The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program, 2012: pp. 389 – 96

Holmfeldt L et al (2013) The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45(3):242–252

Article  PubMed  PubMed Central  Google Scholar 

Marine JC, Lozano G (2010) Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17(1):93–102

Article  PubMed  Google Scholar 

Lu M et al (2013) Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 23(5):618–633

Article  PubMed  Google Scholar 

Ware PL et al (2014) MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors. Am J Clin Pathol 141(3):334–341

Article  PubMed  Google Scholar 

Suzuki A et al (1998) Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 89(2):221–227

Article  PubMed  PubMed Central  Google Scholar 

Zhou M et al (1995) Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 85(6):1608–1614

Article  PubMed  Google Scholar 

Gu L et al (2008) MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 22(4):730–739

Article  PubMed  PubMed Central  Google Scholar 

Oliner JD, Saiki AY, Caenepeel S (2016) The role of MDM2 amplification and overexpression in Tumorigenesis. Cold Spring Harb Perspect Med, 6(6)

Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13(1):23–31

Article  PubMed  Google Scholar 

Vassilev LT et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844–848

Article  PubMed  Google Scholar 

Ding Q et al (2013) Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 56(14):5979–5983

Article  PubMed  Google Scholar 

Ciardullo C et al (2019) Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. Haematologica 104(12):2429–2442

Article  PubMed  PubMed Central  Google Scholar 

Wu CE et al (2018) Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br J Cancer 118(4):495–508

Article  PubMed  Google Scholar 

Zanjirband M, Edmondson RJ, Lunec J (2016) Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget 7(26):40115–40134

Article  PubMed  PubMed Central  Google Scholar 

Chen L et al (2019) Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Int J Cancer 144(12):3146–3159

Article  PubMed  PubMed Central  Google Scholar 

Kojima K et al (2005) MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106(9):3150–3159

Article  PubMed  PubMed Central  Google Scholar 

Aptullahoglu E et al (2024) RNA sequencing reveals candidate genes and pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic lymphocytic leukemia. Biomedicines, 12(7)

Daver NG et al (2023) Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood 141(11):1265–1276

Lakhani SA et al (2006) Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311(5762):847–851

Article  PubMed  PubMed Central  Google Scholar 

Harms KL, Chen X (2006) The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ 13(6):890–897

Article  PubMed  Google Scholar 

Bohlman S, Manfredi JJ (2014) p53-independent effects of Mdm2. Subcell Biochem 85:235–246

Article  PubMed  PubMed Central  Google Scholar 

Thomasova D et al (2012) p53-independent roles of MDM2 in NF-kappaB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 14(12):1097–1101

Article  PubMed  PubMed Central  Google Scholar 

Sabapathy K, Lane DP (2018) Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Reviews Clin Oncol 15(1):13–30

Article  Google Scholar 

Zanjirband M, Rahgozar S, Aberuyi N (2023) Mir-16-5p enhances sensitivity to RG7388 through targeting expression (WIP1) in Childhood Acute Lymphoblastic Leukemia. Cancer Drug Resist 6(2):242–256

Article  PubMed  PubMed Central  Google Scholar 

Kato S et al (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100(14):8424–8429

Article  PubMed  PubMed Central  Google Scholar 

Engeland K (2022) Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ 29(5):946–960

Article  PubMed  PubMed Central  Google Scholar 

Wu X et al (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7(7A):1126–1132

Article  PubMed  Google Scholar 

Aptullahoglu E et al (2023) SF3B1 mutations are Associated with Resistance to non-genotoxic MDM2 inhibition in chronic lymphocytic leukemia. Int J Mol Sci, 24(14)

Lakoma A et al (2015) The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma. Cell Death Discov 1:15026

Qian S et al (2022) The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol 12:985363

Benedict CA, Norris PS, Ware CF (2002) To kill or be killed: viral evasion of apoptosis. Nat Immunol 3(11):1013–1018

Article  PubMed  Google Scholar 

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

Article  PubMed  Google Scholar 

Testa U, Riccioni R (2007) Deregulation of apoptosis in acute myeloid leukemia. Haematologica 92(1):81–94

Article  PubMed  Google Scholar 

Aptullahoglu E et al (2023) Splicing Modulation results in aberrant isoforms and Protein products of p53 pathway genes and the sensitization of B cells to non-genotoxic MDM2 inhibition. Int J Mol Sci, 24(3)

Zanjirband M et al (2017) Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget 8(41):69779–69796

Article  PubMed  PubMed Central  Google Scholar 

Chamberlain V, Drew Y, Lunec J (2021) Tipping growth inhibition into apoptosis by combining treatment with MDM2 and WIP1 inhibitors in p53(WT) Uterine Leiomyosarcoma. Cancers (Basel), 14(1)